Additional Information Index Accounting policies 79, 139, 196 Information Technology 33 Acerta Pharma 75-78, 172-173 Intangible assets 81, 155-157 Acquisitions 173-174 Intellectual Property 32-33 Affordable Care Act 12, 27, 213 Interest-bearing loans and borrowings 161-162 Almirall 76, 163 Key Performance Indicators 17-21 Animal research 42 Leases 189 Annual General Meeting 99, 228 Life-cycle of a medicine 14-16 Articles of Association 116, 231 Litigation 82, 103, 182-188 AstraZeneca at a glance 2-3 Manufacturing and Supply 30-31 Audit Committee 87, 100-104 Market definitions 235 Audit Committee Report 100-104 Marketplace 8-13 Bioethics 41-42 Modern Slavery Act 36 Biologics 12, 19, 22 Non-Financial Reporting Regulations 45 BMS 75-76, 81, 146, 157, 163 Oncology 48-51 Board of Directors 88-89 Operating profit 1, 66-69, 146-147 Business model 14-16 Other Disease Areas 60-62 Cambridge 25 Other investments 158 Capitalisation and shareholder return 78 Patent Expiries 208-209 Cardiovascular & Metabolic Diseases 52-55 Patient safety 42 Cash and cash equivalents 160 Physician Payments Sunshine Act 41 Chairmans Statement 4, 86 Political donations 99 Chief Executive Officers Review 5-7 Post-retirement benefits 82, 164-170 Clinical trials 15, 41 Product revenue information 2, 70, 145, 221-226 Code of Ethics 97-98, 101 Property, plant and equipment 153 Commitments and contingent liabilities 182-188 Precision medicine and genomics 23 Community investment 45 Provisions 164 Company history 229 Regulatory environment 11 Compliance and Internal Audit Services 97-98 Related party transactions 189, 231 Consolidated Statements 135-138 Relations with shareholders 96 Corporate Governance 84-125 Remuneration 105-125 Development pipeline 202-207 Remuneration Policy 109, www.
com  Diabetes 54-55 Research and Development 22-25 Directors interest in shares 116 Reserves 171 Directors responsibility statement 128 Respiratory 56-59 Diversity 35, 93-94 Restructuring 73, 146, 164 Dividends 3, 21, 78, 98, 228 Results of operations 2017 69 Earnings per Ordinary Share 1, 21, 72-73 Risk 63-65, 210-220 Employee costs and share plans for employees 180-181 Sales and Marketing 26-28 Employees 35-37 Sales by geographical area 3, 221-226 Environmental impact 43-44 Sales by therapy area 2, 6, 221-226 Ethics 40-41, 98 Sarbanes-Oxley Act 83 Externalisation 71-72, 145 Science Committee 97 Financial highlights 1 Segment information 151-152 Finance income and expense 147 Senior management SET 87, 90-91 Financial instruments 147 Share capital 99, 171 Financial position 2017 75 Share repurchase 78, 171 Financial Review 66-83 Shareholder information 228-233 Financial risk management 79, 175-179 Strategic priorities 2, 17-21 Financial Statements 2017 135-189 Sustainability: supplementary information 227 Gender diversity 37, 88 Taxation 82, 148-150, 188 Geographical Review 221-226 Taxation information for shareholders 232-233 Glossary 235-238 Trade and other payables 76, 163 Group Financial Record 199 Trade and other receivables 76, 160, 178 Group Subsidiaries and Holdings 190-193 Trade marks 234 Growth Platforms 19, 71 Values and Purpose 14 Healthy Heart Africa programme 29, 40 Young Health Programme 39, 201 Human Rights 36 ZS Pharma 30, 54, 77, 103, 174 Independent auditors report 129-134 AstraZeneca Annual Report & Form 20-F Information 2017 Important information for readers of this Annual Report 239 Important information for readers of this Annual Report Cautionary statement regarding Inclusion of Reported performance, forward-looking statements Core financial measures and constant The purpose of this Annual Report is to exchange rate growth rates provide information to the members of the AstraZenecas determination of non-GAAP Company.
The Company and its Directors, measures together with our presentation employees, agents and advisers do not of them within our financial information accept or assume responsibility to any other may differ from similarly titled non-GAAP person to whom this Annual Report is shown measures of other companies.
or into whose hands it may come and any such responsibility or liability is expressly Statements of competitive position, disclaimed.
In order, among other things, growth rates and sales to utilise the safe harbour provisions of the In this Annual Report, except as otherwise US Private Securities Litigation Reform Act of stated, market information regarding the 1995 and the UK Companies Act 2006, we are position of our business or products relative providing the following cautionary statement: to its or their competition is based upon This Annual Report contains certain forwardpublished statistical sales data for the looking statements with respect to the 12 months ended 30 September 2017 operations, performance and financial obtained from IQVIA, a leading supplier of condition of the Group, including, among statistical data to the pharmaceutical industry.
other things, statements about expected Unless otherwise noted, for the US, revenues, margins, earnings per share or dispensed new or total prescription data and other financial or other measures.
Forwardaudited sales data are taken, respectively, looking statements are statements relating from IQVIA National Prescription Audit to the future which are based on information and IQVIA National Sales Perspectives for available at the time such statements are the 12 months ended 31 December 2017: made, including information relating to risks such data is not adjusted for Medicaid and and uncertainties.
Although we believe that similar rebates.
Except as otherwise stated, the forward-looking statements in this Annual these market share and industry data from Report are based on reasonable assumptions, IQVIA have been derived by comparing our the matters discussed in the forward-looking sales revenue with competitors and total statements may be influenced by factors that market sales revenues for that period, could cause actual outcomes and results to and except as otherwise stated, growth rates be materially different from those expressed are given at CER.
For the purposes of this or implied by these statements.
The forwardAnnual Report, unless otherwise stated, looking statements reflect knowledge and references to the world pharmaceutical information available at the date of the market or similar phrases are to the 54 preparation of this Annual Report and the countries contained in the IQVIA database, Company undertakes no obligation to update which amounted to approximately 96% these forward-looking statements.
We identify in value of the countries audited by IQVIA.
the forward-looking statements by using the words anticipates, believes, expects, AstraZeneca websites intends and similar expressions in such Information on or accessible through our statements.
Important factors that could websites, including www.
com, cause actual results to differ materially www.
com and from those contained in forward-looking www.
com, does not form statements, certain of which are beyond part of and is not incorporated into this our control, include, among other things, Annual Report.
those factors identified in the Risk section from page 210 of this Annual Report.
External third-party websites Nothing in this Annual Report should Information on or accessible through any be construed as a profit forecast.
third-party or external website does not form part of and is not incorporated into this Annual Report.
Figures Figures in parentheses in tables and in the Financial Statements are used to represent negative numbers.
240 AstraZeneca Annual Report & Form 20-F Information 2017 Additional Information Design and production This Annual Report is printed on Heaven Superunion formerly 42 which is FSC certified virgin fibre.
The pulp is a mix: partly bleached using www.
com an Elemental Chlorine Free process and partly bleached using a Totally Chlorine Board photography Free process.
It is printed in the UK by Marcus Lyon Pureprint using its alcofree and pureprint environmental printing technology, and SET photography vegetable inks were used throughout.
Scott Nibauer Pureprint is a CarbonNeutral company.
Graham Carlow Both the manufacturing mill and the printer are registered to the Environmental Management System ISO 14001 and are Forest Stewardship Council chain-ofcustody certified.
Registered office and corporate headquarters AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK Tel: 44 0 20 3749 5000 This Annual Report is also available on our website, www.
